Illustrating reduced insulin resistance, oral simufilam improved the response to insulin of mammalian target of rapamycin (mTOR) and suppressed mTOR’s basal overactivation in lymphocytes of AD subjects [63]. This evidence concerns the gene INS and Alzheimer disease.